Research Papers:

Generation of V α13/β21+T cell specific target CML cells by TCR gene transfer

Xianfeng Zha, Ling Xu, Shaohua Chen, Lijian Yang, Yikai Zhang, Yuhong Lu, Zhi Yu, Bo Li, Xiuli Wu, Wenjie Zheng and Yangqiu Li _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:84246-84257. https://doi.org/10.18632/oncotarget.12441

Metrics: PDF 1896 views  |   HTML 3230 views  |   ?  


Xianfeng Zha1,2,3, Ling Xu2, Shaohua Chen2, Lijian Yang2, Yikai Zhang2, Yuhong Lu4, Zhi Yu4, Bo Li2, Xiuli Wu2, Wenjie Zheng3, Yangqiu Li2,4,5

1Department of Clinical Laboratory, First Affiliated Hospital, Jinan University, Guangzhou, China

2Institute of Hematology, Jinan University, Guangzhou, China

3Department of Chemistry, Jinan University, Guangzhou, China

4Department of Hematology, First Affiliated Hospital, Jinan University, Guangzhou, China

5Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University, Guangzhou, China

Correspondence to:

Yangqiu Li, email: yangqiuli@hotmail.com

Keywords: chronic myeloid leukemia, T cell receptor, gene transfer, immunotherapy

Received: May 02, 2016     Accepted: September 13, 2016     Published: October 04, 2016


Adoptive immunotherapy with antigen-specific T cells can be effective for treating melanoma and chronic myeloid leukemia (CML). However, to obtain sufficient antigen-specific T cells for treatment, the T cells have to be cultured for several weeks in vitro, but in vitro T cell expansion is difficult to control. Alternatively, the transfer of T cell receptors (TCRs) with defined antigen specificity into recipient T cells may be a simple solution for generating antigen-specific T cells. The objective of this study was to identify CML-associated, antigen-specific TCR genes and generate CML-associated, antigen-specific T cells with T cell receptor (TCR) gene transfer. Our previous study has screened an oligoclonal Vβ21 with a different oligoclonal Vα partner in peripheral blood mononuclear cells (PBMCs) derived from patients with CML. In this study, oligoclonally expanded TCR α genes, which pair with TCR Vβ21, were cloned into the pIRES eukaryotic expression vector (TCR Vα-IRES-Vβ21). Next, two recombinant plasmids, TCR Vα13-IRES-Vβ21 and TCR Vα18-IRES-Vβ21, were successfully transferred into T cells, and the TCR gene-modified T cells acquired CML-specific cytotoxicity with the best cytotoxic effects for HLA-A11+ K562 cells observed for the TCR Vα13/Vβ21 gene redirected T cells. In summary, our data confirmed TCRVα13/Vβ21 as a CML-associated, antigen-specific TCR. This study provided new evidence that genetically engineered antigen-specific TCR may become a druggable approach for gene therapy of CML.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 12441